Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Clade A HIV-1 Gag-specific T cell responses are frequent but do not correlate with viral loads in a cohort of treatment-naive HIV-infected individuals living in Guinea-Bissau.

Jensen KJ, Gómez Román VR, Jensen SS, Leo-Hansen C, Karlsson I, Katzenstein TL, Rodrigues CM, Jespersen S, Janitzek CM, Té Dda S, Hayes P, Fomsgaard A.

Clin Vaccine Immunol. 2012 Dec;19(12):1999-2001. doi: 10.1128/CVI.00399-12. Epub 2012 Oct 17. No abstract available.

2.

Assessment of HIV-1 patient recruitability in the Republic of Guinea-Bissau using African versus North American hematology and biochemistry reference intervals.

Gómez Román VR, Jensen SS, Leo-Hansen C, Jensen KJ, Janitzek CM, Rodrigues CM, Jespersen S, Katzenstein TL, Té Dda S, Fomsgaard A.

Clin Vaccine Immunol. 2012 Aug;19(8):1322-5. doi: 10.1128/CVI.00170-12. Epub 2012 Jun 6.

3.

Development of standard operating procedures to obtain longitudinal vaginal specimens from nulliparous rabbits as part of HIV vaccine mucosal immunogenicity studies.

Gómez Román VR, Vinner L, Grevstad B, Hansen JJ, Wegmann F, Spetz AL, Fomsgaard A.

J Immunol Methods. 2010 Dec 15;363(1):29-41. doi: 10.1016/j.jim.2010.09.030. Epub 2010 Sep 29.

PMID:
20887728
4.

An African perspective on mucosal immunity and HIV-1.

Pala P, Gomez-Roman VR, Gilmour J, Kaleebu P.

Mucosal Immunol. 2009 Jul;2(4):300-14. doi: 10.1038/mi.2009.23. Epub 2009 May 6. Review.

PMID:
19421180
5.

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Burke B, Gómez-Román VR, Lian Y, Sun Y, Kan E, Ulmer J, Srivastava IK, Barnett SW.

Virology. 2009 Apr 25;387(1):147-56. doi: 10.1016/j.virol.2009.02.005. Epub 2009 Feb 27.

6.

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

Zhou Q, Hidajat R, Peng B, Venzon D, Aldrich MK, Richardson E, Lee EM, Kalyanaraman VS, Grimes G, Gómez-Román VR, Summers LE, Malkevich N, Robert-Guroff M.

Vaccine. 2007 Nov 19;25(47):8021-35. Epub 2007 Sep 29.

PMID:
17935840
7.

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

Gómez-Román VR, Florese RH, Peng B, Montefiori DC, Kalyanaraman VS, Venzon D, Srivastava I, Barnett SW, Robert-Guroff M.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7.

PMID:
16940858
8.

Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques.

Gómez-Román VR, Grimes GJ Jr, Potti GK, Peng B, Demberg T, Gravlin L, Treece J, Pal R, Lee EM, Alvord WG, Markham PD, Robert-Guroff M.

Vaccine. 2006 Jun 5;24(23):5064-72. Epub 2006 Mar 31.

PMID:
16621178
9.

A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity.

Gómez-Román VR, Florese RH, Patterson LJ, Peng B, Venzon D, Aldrich K, Robert-Guroff M.

J Immunol Methods. 2006 Jan 20;308(1-2):53-67. Epub 2005 Nov 28.

PMID:
16343526
10.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

11.

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies.

Peng B, Wang LR, Gómez-Román VR, Davis-Warren A, Montefiori DC, Kalyanaraman VS, Venzon D, Zhao J, Kan E, Rowell TJ, Murthy KK, Srivastava I, Barnett SW, Robert-Guroff M.

J Virol. 2005 Aug;79(16):10200-9.

12.

Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251.

Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Florese R, Robert-Guroff M.

J Immunol. 2005 Feb 15;174(4):2185-9.

13.

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting.

Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gómez-Román VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M.

J Virol. 2004 Mar;78(5):2212-21.

14.

Adenoviruses as vectors for HIV vaccines.

Gómez-Román VR, Robert-Guroff M.

AIDS Rev. 2003 Jul-Sep;5(3):178-85. Review.

PMID:
14598567
15.

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen.

Zhao J, Pinczewski J, Gómez-Román VR, Venzon D, Kalyanaraman VS, Markham PD, Aldrich K, Moake M, Montefiori DC, Lou Y, Pavlakis GN, Robert-Guroff M.

J Virol. 2003 Aug;77(15):8354-65.

16.
17.

Phage-displayed mimotopes recognizing a biologically active anti-HIV-1 gp120 murine monoclonal antibody.

Gómez-Román VR, Cao C, Bai Y, Santamaría H, Acero G, Manoutcharian K, Weiner DB, Ugen KE, Gevorkian G.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):147-53.

PMID:
12394792
18.

nef/long terminal repeat quasispecies from HIV type 1-infected Mexican patients with different progression patterns and their pathogenesis in hu-PBL-SCID mice.

Gómez-Román VR, Vázquez JA, del Carmen Basualdo M, Estrada FJ, Ramos-Kuri M, Soler C.

AIDS Res Hum Retroviruses. 2000 Mar 20;16(5):441-52.

PMID:
10772530

Supplemental Content

Loading ...
Support Center